| __timestamp | Regeneron Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 205018000 | 5758000 |
| Thursday, January 1, 2015 | 392709000 | 8423000 |
| Friday, January 1, 2016 | 299694000 | 11986000 |
| Sunday, January 1, 2017 | 397061000 | 15215000 |
| Monday, January 1, 2018 | 434100000 | 15356000 |
| Tuesday, January 1, 2019 | 782200000 | 16660000 |
| Wednesday, January 1, 2020 | 1119900000 | 52459000 |
| Friday, January 1, 2021 | 2437500000 | 75061000 |
| Saturday, January 1, 2022 | 1560400000 | 87221000 |
| Sunday, January 1, 2023 | 1815800000 | 83779000 |
| Monday, January 1, 2024 | 1970500000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Regeneron's cost of revenue surged by an impressive 785%, peaking in 2021. This reflects their aggressive expansion and investment in cutting-edge therapies. In contrast, Supernus Pharmaceuticals saw a more modest increase of 1,355% over the same period, highlighting their steady growth strategy.
These trends underscore the diverse strategies employed by pharmaceutical companies to navigate market challenges and opportunities.
Cost of Revenue Comparison: Sanofi vs Supernus Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Bio-Techne Corporation
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Pharming Group N.V.
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and Galapagos NV
Cost of Revenue Comparison: United Therapeutics Corporation vs Supernus Pharmaceuticals, Inc.
Catalent, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Exelixis, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Veracyte, Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc.'s Expenses